microRNA-613调控CDK14来抑制老年胶质瘤患者瘤细胞的增殖和侵袭作用

目的 探讨microRNA-613调控细胞周期蛋白依赖性激酶14(CDK14)通路来抑制老年胶质瘤患者瘤细胞增殖和侵袭的机制。方法 购自上海北诺生物科技有限公司的人脑胶质瘤细胞株U251共24株,分为shNC组、shmicroRNA-613组、Vector组、microRNA-613组,每组各6株; Western Blotting法和qRT-PCR法检测敲减microRNA-613和过表达microRNA-613后的人脑胶质瘤细胞株U251中CDK14蛋白表达水平,CCK-8细胞增殖实验、Transwell小室实验验证敲除microRNA-613和过表达microRNA-613后U251细胞的增殖、侵袭能力。结果 人胶质瘤细胞株U251敲减microRNA-613后CDK14蛋白表达增加(P<0.05); 人胶质瘤细胞株U251过表达microRNA-613后CDK14蛋白表达减少(P<0.05); 转染第24、36、48 h microRNA-613组U251细胞增殖率P<0.05); microRNA-613组U251细胞侵袭能力>Vector组,shNC组>shmicroRNA-613组(P<0.05)。结论 microRNA-613可通过调控CDK14信号转导通路来抑制人脑胶质瘤细胞U251增殖、转移。     

脑心通对脑缺血再灌注损伤细胞外信号调节激酶活化的影响

目的:观察大鼠局灶性脑缺血/再灌注((ischemia/reperfusion,I/R)后信号转导介质细胞外信号调节激酶(extracellular signal-regulated kinase,ERK)的活化情况以及脑心通对其影响。方法:雄性成年Wistar大鼠90只,随机分成3组:假手术组、对照组和脑心通组(每组30只),分别于缺血前6日每日用生理盐水4mL、生理盐水4mL和脑心通0.48g/kg(脑心通用4mL生理盐水溶解)灌胃。采用线栓法致大脑中动脉栓塞(middle cerebral artery occlusion,MCAO)模型,在脑缺血再灌注后的3h、6h、24h、48h和72h分别处死大鼠(各组每个时间点6只),将脑组织进行免疫组织化学、TTC染色,TUNEL法观察细胞凋亡。结果:脑缺血诱导ERK活化,第6h达高峰,并持续到72h。脑心通组ERKs活化明显较对照组增强,而且各时间点ERK免疫反应阳性细胞数脑心通组显著较对照组增多(P<0.01)。脑心通组TTC染色梗死体积及凋亡细胞数较对照组明显较少(P<0.01)。结论:局灶性脑缺血再灌注可诱导缺血脑细胞部分ERK活化,脑心通干预可使缺血大脑海马ERK活化增强,减轻细胞的缺血性损伤。     

A trip through the signaling pathways of melanoma

Many cellular signaling pathways are involved in the development of cancer. Depending on the tumor entity, the nature as well as the mode of activation can differ. Some signaling pathways frequently show changes as all tumor cells have to fulfill some basic requirements such as independence from growth factors or insensitivity against apoptosis. In this review, the possibilities of a tumor to manipulate signaling pathways to reach these goals are exemplified based on an archetypical melanoma cell. In addition, new therapeutic options based on the knowledge of signaling pathways will be discussed.     

反义细胞外信号调节激酶对移植物血管的保护作用

目的探讨反义细胞外信号调节激酶（ERK1／2）基因治疗对移植物血管的保护作用及可能的保护机制。方法建立BN至Lewis大鼠的腹主动脉移植模型。反义ERK1／2治疗组移植前取供者动脉血管段给予经脂质体包装的反义ERK1／2基因转染；腹主动脉移植术后1个月内受者每日从尾静脉或阴茎背静脉注入经脂质体包装的反义ERK1／2寡核苷酸100μl。对照组移植未经任何处理的血管段，移植后也无特殊处理。移植术后60d取移植段主动脉进行组织病理学观察内膜和胶原纤维变化；免疫组织化学法观察移植段血管ERK1／2基因的表达和CD4^＋、CD8^＋T淋巴细胞的浸润情况；ELISA法检测血清中细胞间粘附分子（ICAM-1）的变化。结果移植术后60d，对照组的移植动脉呈慢性移植物血管病表现，血管内膜显著增厚，移植血管中ERK1／2基因高表达，CD4^＋、CD8^＋T淋巴细胞大量浸润；反义ERK1／2基因治疗组移植动脉呈血管内膜炎改变，ERK1／2基因表达不明显，内膜有少量CD4^＋、CD8^＋T淋巴细胞；对照组ICAM-1表达显著高于反义ERK1／2治疗组（P〈0．05）。结论反义ERK1／2基因治疗对移植物血管具有保护作用，可以减缓慢性移植物血管病的发生，这种保护机制可能和减少ICAM-1的表达以及减少移植血管T淋巴细胞的浸润有关。     

Eating to beat breast cancer: Potential role for soy supplements

Background: The study reviews the anticancer properties of naturalisoflavones which occur in especially high concentration in soybeans. Itconsiders the suitability of soybean products for clinical trials aiming toreduce the progression of breast cancer.Methods: Evidence is reviewed that plant isoflavones such asgenistein show cytostatic activity against human mammary cancer cell linesin vitro and can also suppress carcinogen-induced mammary cancer inyoung and mature rats.Results: Plant isoflavones are converted in the bowel to compoundswith potential antioestrogenic and antioxidative properties. These compoundsshow cytostatic activity for both oestrogen receptor-positive and negativehuman mammary cancer cell lines, and also inhibit growth and progress of therat mammary cancer model. The high content of soybean products in the diet ofAsian women has been postulated as one reason for their relatively low breastcancer incidence.Conclusion: Preclinical studies suggest that soybean products begiven priority for clinical trials in breast cancer protection. A pilot studycould test soy protein supplements as long-term adjuvant dietary treatmentafter primary surgery for early breast cancer, looking for a decrease in therisk of recurrence or of second primary tumours.     

腺病毒介导的HSV—tk基因治疗大鼠脑胶质瘤实验研究

目的：带有ＨＳＶ－ｔｋ基因的重组腺病毒（ＡｄＨＣＭＶ－ｔｋ）结合核苷类似物（ＮＡ）治疗大鼠Ｃ６脑胶质瘤。方法：用Ｘ－ｇａｌ染色测定ＡｄＨＣＭＶ－ｌａｃＺ转染大鼠Ｃ６胶质瘤细胞的效率。用ＡｄＨＣＭＶ－ｔｋ／ＡＣＶ、ＧＣＶ离体及活体治疗大鼠Ｃ６胶质瘤。结果：ＡｄＨＣＭＶ－ｌａｃＺ感染Ｃ６细胞效率达１００％，ＡｄＨＣＭＶ－ｔｋ感染Ｃ６细胞，在病毒感染复数为１０００时，ＧＣＶ和ＡＣＶ半致死剂量分别为３μｇ／ｍｌ和２０μｇ／ｍｌ，Ａｄ－ＨＣＭＶ－ｔｋ／ＡＣＶ治疗大鼠Ｃ６胶质瘤模型，大鼠生存期超过９０天，而对照组分别为１７．０±１．６天（生理盐水组）、１４．５±１．３天（ＡｄＨＣＭＶ－ｌａｃＺ组），Ｐ＜０．００１。结论：重组腺病毒对靶细胞感染效率可达１００％，ＡｄＨＣＭＶ－ｔｋ用ＧＣＶ的杀伤Ｃ６胶质瘤细胞比ＡＣＶ强，而ＨＳＶ－ｔｋ／ＡＣＶ用腺病毒介导治疗大鼠脑肿瘤疗效显著。     

IN VITRO ANALYSIS OF τ PHOSPHORYLATION SITES AND ITS BIOLOGICAL ACTIVITY

INTRODUCTIONThemicrotubule－associatedprotein蚲ishyperphos－phorylatedandglycosylatedinAlzheimerdisease（AD），andtheseabnormalmodificationsformedthebasisofprogressivelyretrogradeneurofibrillarydegenerationseeninADbrainandtherebythedementia（１，２）．ADab－normallyphosphorylated蚲notonlyismicrotubuleas－semblyincompetent，butalsoinhibitsassemblyanddis－assemblesthepreassembledmicrotubulesinvitro（３）．Inthetangle－bearingneuronsinADbrain，thenormalcytoskeletonisdisruptedandreplacedwi…     

Neuroprotective properties of valproate

Neuropsychiatric disturbances are extremely common in Alzheimer’s disease (AD), and represent integral features of the illness, as well as appropriate targets for therapy. We are interested in designing trials aimed at preventing or delaying the emergence of psychopathology in AD. For symptomatic treatment of agitation, mood stabilizers, particularly sodium valproate, have proved to be beneficial in some patients. Since these effects take several weeks to emerge, we considered that they might be dependent on potentially neuroprotective actions of valproate, such as inhibition of apoptosis and slowing of neurofibrillary tangle formation. In this article we present the rationale for testing the neuroprotective potential of valproate experimentally in mouse models of tauopathy and in a clinical trial of patients with AD who lack psychopathology at baseline. Together, these studies will provide important tests of the hypothesis that valproate, either through inhibition of tau phosphorylation or some other mechanism, is a useful therapeutic agent to modify disease progression in AD.